贾继东教授对话Peter Ferenci教授

帅庭

内容简介：定义复发不是很容易。我认为你指的是接受了完整聚乙二醇干扰素和利巴韦林治疗，但在治疗中出现抵抗、持续抵抗、在治疗后又出现病毒阳性的患者。这些患者可以被再治疗，而且他们有很高的几率第二次出现应答，特别是如果你更多地关注病毒动力学并把治疗延长到48周以后。如果患者不能耐受药物；或者不能依从治疗；或者有其他问题，例如经济问题等，他们买不起药，中断了治疗，那么你应该尽量优化利巴韦林和干扰素的剂量与依从性之间的问题。


Hepatology Digest: The combination of peginterferon alpha-2a and ribavirin has a good therapeutic effect for the relapse of hepatitis C. For such a population what are issues that require special attention in a clinical setting?

《国际肝病》：对丙肝复发的患者来说，聚乙二醇干扰素与利巴韦林联用有很好的疗效。对这类患者在临床诊治上有什么特别要注意的么？

Prof. Ferenci: The definition of relapse is not so easy. I think you are talking about a patient who received a full course of pegylated interferon and ribavirin, became negative on treatment, remained negative on treatment, and became positive after treatment.
更多精彩内容请点击：http://aphc.ihepa.com/15-159-138.html